761
Views
0
CrossRef citations to date
0
Altmetric
Conference Report

Highlights of the 14th Japan Bioanalysis Forum Symposium

ORCID Icon, , ORCID Icon, , , ORCID Icon, , , ORCID Icon, , , , ORCID Icon, , , , & show all
Pages 1271-1276 | Received 11 Aug 2023, Accepted 30 Aug 2023, Published online: 19 Oct 2023
 

Abstract

The 14th Japan Bioanalysis Forum Symposium was held at Tower Hall Funabori, Japan from 1–3 March 2023. The conference theme, ‘Bringing Together – the Expertise of Bioanalysis’, aimed to enable people from various fields to gather, learn and collaborate together for the common goal of delivering medicines to patients faster. Approximately 360 participants from various fields, including pharmaceutical industries, contractors, academia and regulatory authorities, gathered at an in-person symposium which had an online participation option, for the first time in 4 years. The symposium offered a wide range of topics including ICH M10, new modalities, biomarkers, immunogenicity, electronization and patient-centric sampling. The latest research results were provided from domestic and overseas scientists. This report summarizes the major topics.

Author contributions

T Arakawa: Symposium chair, construction of subparts, writing (original draft, review). Y Nishiguchi: symposium co-chair, construction of subparts, writing (original draft, review). M Hashimoto, M Mabuchi, N Koyama, M Niwa, T Yamaguchi, R Yoshinaga, Y Takamatsu, J Komaba, T Nakamura, T Saito, Y Ohtsu, M Takahashi, R Yagi, S Hanari, Y Hashimoto and S Uchihashi: construction of subparts, writing (original draft, review).

Acknowledgments

The authors thank all presenters for their contribution to an interactive and productive symposium.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.